Company Filing History:
Years Active: 2024-2025
Title: Chanyoung Ock: Innovator in Immune Response Prediction
Introduction
Chanyoung Ock is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of medical technology, particularly in predicting responses to immune anticancer drugs. With a total of 4 patents, his work is paving the way for advancements in cancer treatment.
Latest Patents
Chanyoung Ock's latest patents include innovative methods for predicting patient responses to immune checkpoint inhibitors. One of his patents describes a method that involves receiving a pathology slide image, detecting target items, and determining the immune phenotype of regions within the image. This process generates a prediction regarding whether a patient will respond to the immune checkpoint inhibitor based on the immune phenotype. Another patent focuses on predicting responses based on the density of immune cells, utilizing similar methodologies to assess patient responses effectively.
Career Highlights
Chanyoung Ock is currently associated with Lunit Inc., a company known for its cutting-edge work in medical imaging and artificial intelligence. His role at Lunit Inc. allows him to apply his innovative ideas in a practical setting, contributing to the development of technologies that enhance cancer treatment.
Collaborations
Chanyoung Ock collaborates with talented individuals such as Donggeun Yoo and Jae Hong Aum. These partnerships foster a creative environment that drives innovation and leads to groundbreaking advancements in the medical field.
Conclusion
Chanyoung Ock's contributions to the field of immune response prediction are noteworthy and impactful. His patents and work at Lunit Inc. demonstrate his commitment to improving cancer treatment through innovative technology.